|
tq patechnology search1 technology search technologyKeyword technology Search Result
AI will be difference between winners and losers says new Temenos report | FF News at Sibos
We speak to Temenos Chief Strategy Officer, Kanika Hope, at Sibos 2023 in Toronto, to find out more about their recent Economist Impact report . According to the report, which interviewed bankers acro
Website link :https://adquash.com/news_q.php?str=AI_will_be_difference_between_winners_and_losers_says_new_Temenos_report_|_FF_News_at_Sibos_436
Bevacizumab biosimilar by Gedeon Richter for Metastatic Breast Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 82% phase tra
Website link :https://adquash.com/news_q.php?str=Bevacizumab_biosimilar_by_Gedeon_Richter_for_Metastatic_Breast_Cancer:_Likelihood_of_Approval_693
CBM-588 by Miyarisan Pharmaceutical for Hematopoietic Stem Cell Transplantation: Likelihood of Approval
CBM-588 is under clinical development by Miyarisan Pharmaceutical and currently in Phase I for Hematopoietic Stem Cell Transplantation. According to GlobalData, Phase I drugs for Hematopoietic Stem Ce
Website link :https://adquash.com/news_q.php?str=CBM-588_by_Miyarisan_Pharmaceutical_for_Hematopoietic_Stem_Cell_Transplantation:_Likelihood_of_Approval_695
Golidocitinib by Dizal (Jiangsu) Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung
Website link :https://adquash.com/news_q.php?str=Golidocitinib_by_Dizal_(Jiangsu)_Pharmaceutical_for_Non-Small_Cell_Lung_Cancer:_Likelihood_of_Approval_697
Golidocitinib by Dizal (Jiangsu) Pharmaceutical for Natural Killer Cell Lymphomas: Likelihood of Approval
Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData, Phase II drugs for Natural Killer Ce
Website link :https://adquash.com/news_q.php?str=Golidocitinib_by_Dizal_(Jiangsu)_Pharmaceutical_for_Natural_Killer_Cell_Lymphomas:_Likelihood_of_Approval_700
Epcoritamab by Genmab for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Epcoritamab is under clinical development by and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leu
Website link :https://adquash.com/news_q.php?str=Epcoritamab_by_Genmab_for_Refractory_Chronic_Lymphocytic_Leukemia_(CLL):_Likelihood_of_Approval_701
NKX-019 by Nkarta for Follicular Lymphoma: Likelihood of Approval
NKX-019 is under clinical development by and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 82% phase transition success rate (PTS
Website link :https://adquash.com/news_q.php?str=NKX-019_by_Nkarta_for_Follicular_Lymphoma:_Likelihood_of_Approval_707
NKX-019 by Nkarta for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
NKX-019 is under clinical development by and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinem
Website link :https://adquash.com/news_q.php?str=NKX-019_by_Nkarta_for_Waldenstrom_Macroglobulinemia_(Lymphoplasmacytic_Lymphoma):_Likelihood_of_Approval_708
BNT-142 by BioNTech for Peritoneal Cancer: Likelihood of Approval
BNT-142 is under clinical development by and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR)
Website link :https://adquash.com/news_q.php?str=BNT-142_by_BioNTech_for_Peritoneal_Cancer:_Likelihood_of_Approval_712
BNT-142 by BioNTech for Fallopian Tube Cancer: Likelihood of Approval
BNT-142 is under clinical development by and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate
Website link :https://adquash.com/news_q.php?str=BNT-142_by_BioNTech_for_Fallopian_Tube_Cancer:_Likelihood_of_Approval_713
Imetelstat sodium by Geron for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Imetelstat sodium is under clinical development by and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20%
Website link :https://adquash.com/news_q.php?str=Imetelstat_sodium_by_Geron_for_Relapsed_Acute_Myeloid_Leukemia:_Likelihood_of_Approval_714
How was mRNA research used to fight COVID? | Explained
The story so far: On October 2, Nobel Prize week began with the 2023 Prize in Physiology or Medicine being awarded to Katalin Karikó and Drew Weissman. They were awarded the prize for their “discov
Website link :https://adquash.com/news_q.php?str=How_was_mRNA_research_used_to_fight_COVID_|_Explained_204